Daré Bioscience (NASDAQ: DARE) announced a collaboration with MyMenopauseRx, a telehealth platform focused on menopause care, to offer women an additional care pathway alongside its DARE to PLAY Sildenafil Cream product.

Under the agreement, MyMenopauseRx will be featured as a menopause-specific telehealth option for women exploring DARE to PLAY. Through the partnership, women can access menopause specialists offering lifestyle counseling and bioidentical hormonal treatment, available through commercial insurance or cash pay. The option complements DARE to PLAY's existing telehealth questionnaire and the option to consult a personal provider.

MyMenopauseRx currently operates in 42 states, with most of its services covered by commercial insurance.

"Women should not have to navigate menopause alone, and they should not have to shoulder the search for a knowledgeable provider by themselves," said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. "Every woman's needs are different, and we want to meet her wherever she is."

"We are proud to collaborate with Daré Bioscience around our shared commitment to giving women better access to high-quality menopause care," said Dr. Barbra Hanna, Co-Founder and Chief Executive Officer of MyMenopauseRx. "Together with Daré, we can reach more women, expand awareness and help make specialized menopause care easier to find."

The collaboration is part of Daré's stated strategy to build a commercial ecosystem connecting its products with education and access to specialized care providers. The company said it expects the partnership to expand its commercial reach and consumer engagement.